Claims for Patent: 6,686,196

Summary for Patent: 6,686,196

Title:	Recombinant, modified adenoviral vectors for tumor specific gene expression and uses thereof
Abstract:	This invention provides modified recombinant Ad vectors (e.g., AdE1- vectors) undergoing defined homologous recombination in order to create predictably rearranged genomic derivatives in a host cell. Genomic rearrangements can be achieved, for example, by incorporating two IR sequences within one vector genome and enabling genomic rearrangement by coinfection with two parental vectors of one type (also referred to herein as a one vector system) or by homologous recombination of overlapping regions in two distinct types of parental vectors (with or without IR sequences) and enabling genomic rearrangement only upon coinfection of the host cell with the two distinct parental vectors (also referred to herein as two vector system).
Inventor(s):	Lieber; Andre (Seattle, WA), Steinwaerder; Dirk S. (Hamburg, DE), Carlson; Cheryl A. (Seattle, WA), Mi; Jie (Seattle, WA)
Assignee:	University of Washington (Seattle, WA)
Application Number:	09/849,106
Patent Claims:	1. A recombinant adenovirus vector comprising in order: a. an adenovirus left inverted terminal repeat sequence; b. an adenovirus packaging sequence; c. a heterologous promoter sequence which mediates transcription in a direction away from the adenoviral left inverted terminal repeat sequence in step a; d. a first inverted repeat sequence; e. a foreign DNA sequence to be transcribed and which is in an antisense orientation relative to the promoter sequence of step c; f. a second inverted repeat sequence; g. a gene or genes that mediates replication of the adenovirus in a transduced cell; and h. an adenovirus right inverted terminal repeat sequence. 2. The recombinant adenovirus vector of claim 1 further comprising a transcriptional stop site sequence located downstream of the first inverted repeat sequence, wherein the transcriptional stop site sequence arrests transcription of the foreign DNA sequence. 3. The recombinant adenovirus vector of claim 1, wherein the promoter sequence is tumor specific. 4. The recombinant adenovirus vector of claim 1, wherein the promoter sequence is a Rous Sarcoma Virus promoter sequence. 5. The recombinant adenovirus vector of claim 2, wherein the transcriptional stop site sequence is an SV40 bi-directional polyadenylation sequence. 6. The recombinant adenovirus vector of claim 2, wherein the transcriptional stop site sequence is a synthetic bi-directional polyadenylation stop site sequence. 7. The recombinant adenovirus vector of claim 1, wherein the first and second inverted repeat sequences are the same sequence. 8. The recombinant adenovirus vector of claim 1, wherein the first and second inverted repeat sequences encode excisable RNA sequences. 9. The recombinant adenovirus vector of claim 8, wherein the first and second inverted repeat sequences are a .beta.-globin intron. 10. The recombinant adenovirus vector of claim 8, wherein the inverted repeat sequences are intron sequences with splice acceptor and splice donor site. 11. The recombinant adenovirus vector of claim 1, wherein the foreign DNA sequence encodes a gene product. 12. The recombinant adenovirus vector of claim 11, wherein the gene product is a pro-apoptotic gene product or a cytolytic gene product. 13. The recombinant adenovirus vector of claim 11, wherein the gene product is a .beta.-galactosidase gene product. 14. The recombinant adenovirus vector of claim 11, wherein the gene product is a suicide gene product. 15. The recombinant adenovirus vector of claim 11, wherein the gene product is a dominant negative i-.kappa.-.beta. gene product. 16. The recombinant adenovirus vector of claim 11, wherein the gene product is a caspase gene product. 17. The recombinant adenovirus vector of claim 16, wherein the caspase gene product is a caspase-3 gene product or a caspase-6 gene product. 18. The recombinant adenovirus vector of claim 11, wherein the gene product is a radioisotope concentrator protein. 19. The recombinant adenovirus vector of claim 11, wherein the gene product is a fusion protein containing a toxic moiety and a HSV VP22 protein. 20. The recombinant adenovirus vector of claim 11, wherein the gene product is a human .beta.-glucuronidase. 21. The recombinant adenovirus vector of claim 1, wherein the genes that mediate replication of the adenovirus in the transduced cell are E1, E2, and E4. 22. The recombinant adenovirus vector of claim 1, wherein the genes that mediate replication of the adenovirus in the transduced cell are E2, E3, and E4. 23. The recombinant adenovirus vector of claim 1, wherein the genes that mediate replication of the adenovirus in the transduced cell are E2 and E4. 24. The recombinant adenovirus vector of claim 1, further comprising an insulator DNA element. 25. The recombinant adenovirus vector of claim 24, wherein the insulator DNA element is a chicken .UPSILON.-globin insulator DNA element. 26. The recombinant adenovirus vector of claim 24, wherein the insulator DNA element is a Drosophila melanogaster gypsy insulator DNA element.

Details for Patent 6,686,196

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2020-05-03
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2020-05-03
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2020-05-03